Alembic Pharmaceuticals’ associate company -- Rhizen Pharmaceuticals SA -- has received Fast Track Designation for RP6530 (tenalisib) from United States Food & Drug Administration (USFDA). RP6530 (tenalisib) is a highly selective and orally active dual PI3K delta/gamma inhibitor, for the treatment of patients with relapsed/refractory peripheral T-cell lymphoma (PTCL).
Fast Track Designation is awarded to drugs that treat a serious condition and fill an unmet medical need. Fast Track Designation enables the recipient to have more frequent interaction with and support from FDA, both through meetings and written communications, and also makes the drug eligible for Accelerated Approval and Priority Review.
Alembic Pharmaceuticals, a vertically integrated research and development pharmaceutical company, has been at the forefront of Healthcare since 1907. The company manufactures and markets generic pharmaceuticals products all over the world.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1660.00 |
| Dr. Reddys Lab | 1220.00 |
| Cipla | 1234.40 |
| Zydus Lifesciences | 931.00 |
| Lupin | 2305.80 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: